Total Payments
$134,471
2023 Payments
$4,969
Companies
14
Transactions
145
Medicare Patients
1,965
Medicare Billing
$3.4M
Payment Breakdown by Category
Consulting$92,756 (69.0%)
Other$27,814 (20.7%)
Research$5,481 (4.1%)
Travel$4,819 (3.6%)
Food & Beverage$2,748 (2.0%)
Education$855.00 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $92,756 | 30 | 69.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,814 | 8 | 18.5% |
| Unspecified | $5,481 | 38 | 4.1% |
| Travel and Lodging | $4,819 | 18 | 3.6% |
| Honoraria | $3,000 | 1 | 2.2% |
| Food and Beverage | $2,748 | 49 | 2.0% |
| Education | $855.00 | 1 | 0.6% |
Payments by Type
General
$128,990
107 transactions
Research
$5,481
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42,050 | 30 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $40,378 | 75 | $0 (2021) |
| GENZYME CORPORATION | $23,312 | 6 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $14,261 | 9 | $0 (2023) |
| Seattle Genetics, Inc. | $3,729 | 7 | $0 (2017) |
| Merck Sharp & Dohme LLC | $2,250 | 2 | $0 (2022) |
| BioNTech SE | $2,153 | 2 | $0 (2023) |
| F. Hoffmann-La Roche AG | $1,929 | 2 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $1,721 | 1 | $0 (2018) |
| Eisai Inc. | $1,719 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $4,969 | 7 | BioNTech SE ($2,153) |
| 2022 | $10,702 | 8 | E.R. Squibb & Sons, L.L.C. ($9,552) |
| 2021 | $27,037 | 25 | E.R. Squibb & Sons, L.L.C. ($21,640) |
| 2020 | $23,255 | 23 | Regeneron Pharmaceuticals, Inc. ($14,098) |
| 2019 | $17,224 | 31 | Regeneron Pharmaceuticals, Inc. ($15,278) |
| 2018 | $37,328 | 29 | GENZYME CORPORATION ($15,874) |
| 2017 | $13,955 | 22 | E.R. Squibb & Sons, L.L.C. ($10,101) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/30/2023 | BioNTech SE | — | Food and Beverage | In-kind items and services | $53.40 | General |
| 11/29/2023 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 08/25/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,965.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 06/15/2023 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Oncology | ||||||
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 12/16/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 11/21/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2022 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| 09/29/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $111.20 | General |
| 07/26/2022 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| 07/13/2022 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $707.48 | General |
| 07/13/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $103.67 | General |
| 06/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $10.00 | General |
| 11/09/2021 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| 10/25/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/21/2021 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $119.42 | General |
| 10/14/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 09/10/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,620.00 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $136.01 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/16/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 08/04/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $132.69 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/02/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $162.50 | General |
| 07/16/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $23.22 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $4,853 | 28 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $627.12 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 456 | 30,381 | $3.4M | $1.1M |
| 2022 | 14 | 506 | 29,819 | $3.5M | $1.1M |
| 2021 | 17 | 576 | 32,327 | $2.6M | $827,099 |
| 2020 | 10 | 427 | 13,832 | $1.3M | $346,283 |
Total Patients
1,965
Total Services
106,359
Medicare Billing
$3.4M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 25,780 | $1.9M | $610,229 | 31.6% |
| J9228 | Injection, ipilimumab, 1 mg | Office | 2023 | 11 | 2,650 | $1.0M | $345,516 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 417 | $177,225 | $46,800 | 26.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 38 | 187 | $105,655 | $23,538 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 83 | 144 | $43,200 | $11,639 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $30,800 | $8,964 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 28 | $15,400 | $4,510 | 29.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 202 | $20,200 | $2,945 | 14.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 40 | $10,000 | $2,886 | 28.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 40 | $11,200 | $2,473 | 22.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 785 | $1,570 | $74.71 | 4.8% |
| J3490 | Unclassified drugs | Office | 2023 | 18 | 64 | $3,200 | $40.91 | 1.3% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2022 | 19 | 24,620 | $1.8M | $572,432 | 31.0% |
| J9228 | Injection, ipilimumab, 1 mg | Office | 2022 | 11 | 3,450 | $1.3M | $441,962 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 278 | $106,845 | $31,000 | 29.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 84 | 185 | $92,060 | $29,473 | 32.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 37 | 169 | $95,485 | $22,669 | 23.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 30 | 79 | $12,640 | $12,613 | 99.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 67 | 90 | $24,060 | $7,006 | 29.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $21,800 | $5,919 | 27.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 19 | 158 | $15,800 | $2,415 | 15.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 21 | 22 | $2,750 | $1,847 | 67.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 13 | 24 | $6,720 | $1,556 | 23.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 13 | 14 | $1,120 | $715.94 | 63.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 16 | 631 | $1,262 | $59.56 | 4.7% |
About Dr. Anna Pavlick, DO
Dr. Anna Pavlick, DO is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255332839.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Pavlick, DO has received a total of $134,471 in payments from pharmaceutical and medical device companies, with $4,969 received in 2023. These payments were reported across 145 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($92,756).
As a Medicare-enrolled provider, Pavlick has provided services to 1,965 Medicare beneficiaries, totaling 106,359 services with total Medicare billing of $3.4M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 08/09/2005
- Last Updated 05/02/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255332839
Products in Payments
- LIBTAYO (Biological) $37,126
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $19,701
- ONCOLOGY MEDICAL (Drug) $10,338
- OPDIVO (Biological) $7,383
- LIBTAYO (Drug) $5,536
- KEYTRUDA (Biological) $2,250
- Zelboraf (Biological) $1,929
- Lenvima (Drug) $1,719
- MEKTOVI (Drug) $102.95
- Erivedge (Biological) $25.51
- ROLVEDON (Drug) $22.46
- Braftovi (Drug) $20.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205